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Abstract 
The differentiation of fibroblasts into a transient population of highly activated extracellular 
matrix (ECM) producing myofibroblasts at sites of tissue injury is critical for normal tissue 
repair.  Excessive myofibroblast accumulation and persistence, often as a result of a failure to 
undergo apoptosis when tissue repair is complete, leads to pathological fibrosis and is also a 
feature of the stromal response in cancer.  Myofibroblast differentiation is accompanied by 
changes in cellular metabolism, including increased glycolysis, to meet the biosynthetic demands 
of enhanced ECM production.  Here we show that transforming growth factor-β1 (TGF-β1), the 
key pro-fibrotic cytokine implicated in multiple fibrotic conditions, increased the production of  
activating transcription factor 4 (ATF4), the transcriptional master regulator of amino acid 
metabolism, in order to supply glucose-derived glycine to meet the amino acid requirements 
associated with enhanced collagen production in response to myofibroblast differentiation. We 
further delineate the signaling pathways involved and show that TGF-β1–induced ATF4 
production was dependent on the cooperation between canonical TGF-β1 signaling through 
Smad3 and activation of the mechanistic target of rapamycin complex 1 (mTORC1) and 
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) axis.  ATF4 in turn 
promoted a transcriptional enhancement of the de novo serine-glycine biosynthetic pathway, as 
well as the glucose transporter 1 (GLUT1).  Our findings suggest that targeting the TGF-β1–
mTORC1–ATF4 axis may represent a novel therapeutic strategy for interfering with 
myofibroblast function in fibrosis and potentially in other conditions, including cancer.   
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Introduction 
 
Fibrosis is the concluding pathological outcome and major cause of morbidity and 
mortality in a number of common chronic inflammatory, immune-mediated and metabolic 
diseases (1). The perpetual and relentless deposition of a collagen-rich matrix is the cornerstone 
of the fibrotic response and eventually leads to organ failure and premature death.  Despite the 
rising incidence of fibrotic disease and intense research efforts, there remains a paucity of 
effective treatment options.  Idiopathic pulmonary fibrosis (IPF) represents the most rapidly 
progressive and lethal of all fibrotic diseases and is associated with a dismal median survival of 3 
years from diagnosis (2, 3). Although the approval of pirfenidone and the small molecule 
tyrosine kinase inhibitor, nintedanib, for the treatment of IPF represented a watershed moment 
for the development of anti-fibrotic therapeutics, these agents slow but do not halt disease 
progression (4, 5). Therefore, there remains a pressing need to identify novel anti-fibrotic 
therapeutic strategies (6).   
 
Myofibroblasts are the key effector cells responsible for the synthesis and deposition of a 
collagen-rich ECM during normal wound healing, as well as during the development of 
pathological tissue fibrosis (7). Myofibroblasts can be derived from multiple cell types, including 
tissue resident fibroblasts, and are characterized by the de novo production of  
α-smooth muscle actin (α-SMA) which assimilates into stress fibers giving rise to their 
contractile phenotype (reviewed in (8)). The excessive accumulation and persistence of these 
ECM producing myofibroblasts, as a result of a dysregulated wound healing response 
perpetuated by a network of proliferation and differentiation signals within a homeostatically 
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dysregulated tissue microenvironment, represents a key common mechanism underlying the 
development of pathological fibrosis.  Myofibroblasts are also integral to the epithelial-
mesenchymal cross-talk as part of the stromal reaction in epithelial tumors (9) and current 
evidence suggests that the presence of stromal myofibroblasts is generally associated with poor 
prognosis in solid cancers (10).  
Metabolic reprogramming is a hallmark of cancer but is now increasingly recognized as 
playing a key role in dictating cell fate and function in the context of inflammation and immunity 
(11). Evidence for altered metabolism in the context of fibrosis has also emerged.  Indeed, 18F-
fluorodeoxyglucose ([18F]-FDG) uptake by positron emission tomography (PET), a commonly 
used imaging marker of enhanced glycolysis in cancer, has been reported to be increased in IPF 
patients (12, 13) and is predictive of progression-free survival (14). Although multiple cell types 
might be responsible for the increased uptake of [18F]-FDG in IPF, glycolysis has been shown to 
be increased during TGF-β1-induced myofibroblast differentiation in vitro and targeting 
glycolysis attenuated experimental lung fibrosis (15, 16). However, the mechanisms that regulate 
metabolic reprogramming in fibrosis remain poorly understood .  
The serine-threonine kinase, mechanistic target of rapamycin (mTOR), plays a key role in 
regulating cell metabolism, along with other key cellular processes, including cell cycle 
progression, proliferation, growth, autophagy and protein synthesis.  mTOR is central to two 
distinct complexes, mTORC1 and mTORC2, which integrate critical environmental and 
intracellular cues provided by nutrients, energy, oxygen and growth factors (recently reviewed in 
(17)). mTOR signaling is commonly dysregulated in human disease and has been strongly 
implicated in coordinating metabolic reprogramming in cancer cells in order to optimize nutrient 
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uptake and utilization, and meet the biosynthetic needs of proliferative cancer cells (18–20). This 
has led to major interest in targeting mTOR in the setting of cancer, as reflected by the growing 
number of ATP-competitive mTOR inhibitors that are either approved or in clinical development 
(17, 21, 22).  
mTOR signaling has also been implicated in fibrosis (23–25); however, whether mTOR 
contributes to the development of fibrosis as a result of its well-recognized immuno-modulatory 
functions or by influencing fibroblast ECM deposition directly is still unclear. Studies from our 
laboratory provided strong scientific rationale for progressing the potent pan-PI3K-mTOR 
inhibitor, Omipalisib, to a first-in-human proof of mechanism trial in patients with IPF 
(clinicaltrials.gov/NCT01725139), based on the potential of this compound to interfere with 
fibroblast function, including collagen deposition induced in response to the potent fibrogenic 
mediator, TGF-β1 (26). We subsequently showed that the translational mTORC1-4E-BP1 axis is 
critical for TGF-β1–induced collagen synthesis in fibroblasts (27). However, the underlying 
mechanism(s) by which mTORC1 influences this response remains poorly understood.  
In the current study, we used an unbiased bioinformatics approach to identify key 
transcriptional modules that are induced in response to TGF-β1 and modulated by mTOR 
inhibition.  We report a critical mechanistic pathway linking mTORC1 activation to altered 
myofibroblast metabolism through the transcriptional master regulator of amino acid 
metabolism, activating transcription factor 4 (ATF4), in order to fuel ECM biosynthesis.  These 
findings shed novel light on the signaling pathways by which TGF-β1 influences collagen 
deposition with important implications for the future development of novel therapeutic strategies 
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for multiple conditions associated with the abnormal accumulation of myofibroblasts and 
excessive matrix deposition. 
 
Results  
 
mTOR enhances expression of glycine biosynthesis genes in TGF-β1–stimulated fibroblasts 
 
We have shown that rapamycin-insensitive mTORC1 signaling is critical for TGF-β1–induced 
collagen deposition (26, 27). To define the underlying mechanism, we applied weighted gene co-
expression network analysis (WGCNA) using Metacore™ to interrogate our existing RNAseq 
(GSE102674) dataset, which compares the global transcriptomic effect of the highly-selective 
ATP-competitive mTOR inhibitor, AZD8055, to rapamycin in human lung fibroblasts exposed 
to TGF-β1.  
WGCNA revealed 65 independent sets of highly correlated genes (also referred to as co-
expression modules). For each of these modules, the measure of central tendency (the eigengene) 
correlated to a requisite profile showing complete reversal of the TGF-β1 response by AZD8055 
and no reversal by rapamycin. This led to the identification of a single module with the highest 
correlation (r=0.99) (Fig. 1A). Pathway analysis revealed that this module was enriched for three 
amino-acid synthesis pathways (serine-glycine, alanine-cysteine and cysteine-glutamine) with 
the serine-glycine biosynthesis pathway representing the most enriched pathway (Fig. 1B and 
Table S1).  Expression of the serine-glycine biosynthetic pathway genes, phosphoglycerate 
dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1), phosphoserine 
phosphatase (PSPH) and serine hydroxymethyltransferase (SHMT) 2 were all increased 
following TGF-β1 treatment. This increase was inhibited by AZD8055 treatment, whereas 
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rapamycin had no effect (Fig. 1C), indicating that rapamycin-insensitive mTOR signaling may 
play a critical role in enhancing the expression of genes involved in serine and glycine 
biosynthesis in response to TGF-β1 stimulation. 
The original RNAseq dataset and our previous work demonstrating a key role for rapamycin 
insensitive mTORC1 signaling during TGF-β1–stimulated collagen deposition were generated in 
primary human lung fibroblasts (pHLFs) cultured in standard DMEM (25mM glucose; 2mM 
glutamine)(27). Because mTOR is sensitive to environmental signals, including energy and 
nutrient abundance and in view of the profound effects of mTOR inhibition on the transcriptome 
of multiple metabolic genes (reviewed in (28)), we performed all subsequent functional studies at 
physiological concentrations of glucose (5mM) and glutamine (0.7mM). We confirmed that 
under these conditions, TGF-β1 caused a marked increase in mTORC1 signaling in pHLFs as 
evidenced by p70S6K(Thr389) and 4E-BP1(Ser65) phosphorylation (Fig.1D and fig.S1, A and B).  
TGF-β1 also increased collagen deposition by 251 +/- 8.6%, as determined in a well-
characterized quantitative assay based on high content imaging of collagen I immunostaining at 
48 hours (26) (Fig. 1, E and F).  ATP-competitive mTOR inhibition with AZD8055 attenuated 
TGF-β1–induced collagen deposition in a concentration-dependent manner with an IC50 of 
340nM (Fig. 1E) whereas rapamycin had no effect (Fig. 1G). We also investigated whether 
mTOR regulated TGF-β1–induced myofibroblast differentiation, based on the assessment of α-
SMA by high content imaging.  As expected TGF-β1 increased fibroblast α-SMA production, but 
AZD8055 did not block this response (fig. S1, C and D).   
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In agreement with our RNASeq dataset, under physiological glucose and glutamine 
concentrations, mRNA abundance of all the enzymes involved in serine-glycine biosynthesis, 
PHGDH, PSAT1, PSPH and SHMT2 were significantly increased in response to TGF-β1 
stimulation at 24 hours (Fig. 2, A to D).  In contrast, SHMT1, which preferentially converts 
glycine to serine (29), was not influenced by TGF-β1 treatment (fig. S1E).  The TGF-β1–induced 
increase in mRNA abundance of the serine-glycine pathway enzymes was sensitive to inhibition 
by AZD8055 but insensitive to rapamycin treatment (fig. S1, F to I).  Evaluation of the effect of 
TGF-β1 at the protein level confirmed that the rate-limiting enzymes, PHGDH and PSPH, were 
increased in response to TGF-β1–stimulation at 24 hours and that these increases were inhibited 
by AZD8055 (Fig. 2, E and F). 
Overconnected node analysis reveals a key role for mTOR in promoting ATF4 protein 
production 
We next explored the potential mechanism by which rapamycin-insensitive mTOR promotes the 
de novo serine-glycine synthesis pathway in response to TGF-β1 stimulation. To this end, we 
first employed overconnected node analysis (OCN) based on the MetaCore™ database of 
curated literature gene and protein interactions in order to identify potential master regulators of 
gene expression. Using the principles of enrichment analysis (i.e. Fisher’s Exact Test), a p-value 
was calculated for each gene in the database by comparing the overlap of its known interactors 
with the gene list of interest. OCN of the RNAseq dataset revealed a cluster of transcription 
factors associated with the serine-glycine metabolism module of enriched mRNAs, including the 
transcription factor, ATF4 (Fig. 3A). ATF4 is a known mTOR-responsive gene and a key 
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effector of the stress response that triggers increased gene transcription by binding to the C/EBP-
ATF response element (CARE) in specific genes, including all enzymes of the de novo serine-
glycine synthesis pathway (30, 31). We therefore next examined whether ATF4 was the 
downstream target of mTOR involved in mediating the TGF-β1––induced increase in de novo 
glycine biosynthesis and collagen deposition. 
We first examined the relationship between ATF4 and TGF-β1, as ATF4 is not known to be a 
TGF-β1––responsive gene in fibroblasts.  ATF4 mRNA abundance was significantly increased 
by 2.60 ± 0.37-fold and by 2.02 ± 0.12-fold in TGF-β1––stimulated cells relative to media alone- 
treated cells at 12 and 24 hours, respectively (Fig. 3B).  At the protein level, ATF4 was barely 
detectable in media alone-treated cells by immunoblotting. In contrast, in TGF-β1–stimulated 
cells, ATF4 was abundant at all time points examined from 8 hours onwards (Fig. 3C).  
We next examined whether TGF-β1––induced ATF4 was sensitive to ATP-competitive mTOR 
inhibition.  AZD8055 had no effect on TGF-β1––induced ATF4 mRNA abundance (Fig. 3D) but 
completely blocked ATF4 protein production at all time points examined (Fig. 3, E and F). We 
also examined the contribution of canonical TGF-β1 signaling through the Smad pathway. 
Silencing Smad3 using siRNA completely inhibited the increase in ATF4 mRNA abundance at 
24 hours as well as protein production assessed at 8 and 24 hours (Fig. 3, G to I, fig. S2A). 
Taken together these data led us to conclude that TGF-β1–induced ATF4 production is both 
Smad3 and mTOR dependent and further that mTOR is acting at the post-transcriptional level.  
 
We next explored the possibility that mTOR might be influencing ATF4 protein stability.  To 
this end, we assessed the impact of AZD8055 on the rate of decline of ATF4 abundance in the 
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presence of the translation inhibitor, lactimidomycin (LTM).  Both compounds were added at 13 
hours post TGF-β1––stimulation to allow ATF4 protein to accumulate.  ATF4 protein abundance 
was then monitored at different time points over an hour. These experiments revealed that 
AZD8055 did not influence the rate at which ATF4 protein levels declined in the presence of 
LTM and therefore allowed us to conclude that mTOR is not acting by promoting ATF4 protein 
stability (Fig. 3J and fig. S2B).   
 
We also sought to identify the mTOR complex involved in mediating the TGF-β1 induced ATF4 
response. To this end, we generated RPTOR and RICTOR-deficient fibroblasts by CRISPR-Cas9 
gene editing to specifically disrupt either mTORC1 or mTORC2 signaling, respectively. 
Efficient gene-editing was confirmed by western blotting (fig. S2C). TGF-β1––induced ATF4 
protein synthesis was significantly abrogated in RPTOR-edited fibroblasts but fully maintained 
in RICTOR-deficient fibroblasts, indicating that TGF-β1 exerts its stimulatory effects on ATF4 
production exclusively through an mTORC1-dependent mechanism (Fig. 3K).  We next 
interrogated the role of 4E-BP1 downstream of mTORC1, by generating pHLFs expressing a 
doxycycline-inducible 4E-BP1 dominant negative phospho-mutant (with mTORC1 
phosphorylation sites replaced by alanine, abbreviated as 4E-BP1-4A) (27).  We have previously 
confirmed that doxycycline treatment induces 4E-BP1-4A expression in transduced pHLFs and 
leads to inhibition of cap-dependent translation (27). We now show that TGF-β1–induced ATF4 
protein production was completely abrogated in 4E-BP1-4A transduced pHLFs (Fig. 3L). These 
effects were not related to inhibition of ATF4 by doxycycline treatment since doxycycline 
treatment did not inhibit TGF-β1–induced ATF4 protein production in untransduced pHLFs (fig. 
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S2D).  Taken together, these data demonstrate that the translational mTORC1-4E-BP1 axis is 
critical for TGF-β1––induced ATF4 protein synthesis.  
 
We also examined whether the ATF4 response to TGF-β1 was downstream of the classical stress 
response involving PERK activation and subsequent eIF2α phosphorylation. However, this 
possibility was ruled out on the evidence that TGF-β1 had no effect on eIF2α phosphorylation 
compared to unstimulated fibroblasts over 12 hours (fig. S2E).  Furthermore, the PERK 
inhibitor, GSK2656157, did not inhibit TGF-β1––induced collagen deposition (fig. S2F).  
 
Having demonstrated that ATF4 is enhanced in TGF-β1–activated myofibroblasts in vitro, we  
questioned whether this observation holds potential translational significance in the clinical 
setting of fibrosis in humans.  To this end we used double immunofluorescence to determine 
whether ATF4 and the myofibroblast differentiation marker, α-SMA were co-expressed by the 
same cells in IPF fibrotic foci, the cardinal lesions and leading edge of the fibrotic response. 
These studies revealed that ATF4 immunofluorescence was consistently and widely expressed in 
the IPF lung and was associated with α-SMA positive myofibroblasts within fibrotic foci, as well 
as with the hyperplastic alveolar epithelium overlying fibrotic foci (Fig. 4, A to C). In control 
lung parenchyma, ATF4 was largely found to be expressed by the alveolar epithelium (Figure 
4D).  Myofibroblasts are generally not found in normal lung but high magnification images of 
myofibroblasts within IPF fibrotic foci demonstrate that ATF4 in myofibroblasts was localized to 
both the cytoplasm and the nucleus (Figure 4, panels E to H). 
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ATF4-dependent modulation of the serine-glycine pathway is critical for TGF-β1–induced 
collagen deposition 
We next examined whether ATF4 plays a role in influencing glycine biosynthesis during TGF-
β1––induced collagen deposition. Using chromatin-bound protein fractionation, we first 
confirmed that ATF4 was predominantly associated within the chromatin fraction in TGF-β1–– 
stimulated cells (Fig. 5A).  Silencing ATF4 using siRNA (Fig. 5B) suppressed the TGF-β1–– 
induced increase in PHGDH, PSAT1, PSPH and SHMT2 mRNA and protein abundance (Fig. 5, 
C to G and fig. S3, A to E) as well as TGF-β1–– induced collagen deposition (Fig. 5, H to I). In 
order to control for potential off-target effects with siRNA, we also used CRISPR-Cas9 gene 
editing to silence ATF4. This approach similarly demonstrated that ATF4-deficient cells were 
unable to increase collagen production in response to TGF-β1 stimulation (Fig. 5J and fig. S3F). 
Taken together these data suggest that ATF4 mediates the fibrogenic effects of TGF-β1 by 
enhancing the de novo serine-glycine pathway.  
 
mTOR amplifies glucose metabolism during TGF-β1––induced fibroblast collagen synthesis 
through an ATF4-dependent mechanism 
In addition to increased expression of genes encoding serine-glycine biosynthetic enzymes, 
increased substrate availability is also necessary for increased metabolic pathway activity. 
Glycine can be synthesised de novo from glucose (32) and in our RNAseq dataset, the gene 
SLC2A1, which encodes the facilitative glucose transporter, GLUT1, was present in the same 
WGCNA module as the serine-glycine pathway genes and followed the same pattern of 
induction with TGF-β1, inhibition of induction in the presence of AZD8055 and insensitivity to 
rapamycin (Fig.1C). We therefore next considered whether rapamycin-insensitive mTOR 
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signaling downstream of TGF-β1 increases glucose uptake to support increased glycine 
biosynthesis during TGF-β1––induced collagen deposition. 
 
TGF-β1 stimulation of fibroblasts led to an increase in glycolytic flux, extracellular acidification 
rate (ECAR) and oxygen consumption rate (OCR) (Fig. 6, A to C).  This was associated with 
increased glucose uptake, SLC2A1 mRNA abundance, GLUT1 protein production and 
expression of genes encoding the glycolytic enzymes, PFKFB3 and LDHA (fig. S4, A to E).  
The TGF-β1––induced collagen response was decreased by 82 ± 11 % in media devoid of 
glucose (Fig. 6D) and by 90 ± 7% in the presence of the glycolytic inhibitor, 2-deoxyglucose 
(2DG) (fig. S4F), indicating that glycolysis is required for TGF-β1––induced collagen 
deposition. In contrast, the mitochondrial complex I and III inhibitors, rotenone and antimycin A, 
had no effect on TGF-β1–induced collagen deposition (Fig. 6E), despite inhibiting the TGF-β1––
induced increase in OCR (Fig. 6C). Taken together, these data led us to conclude that glycolysis, 
but not mitochondrial respiration, is necessary for TGF-β1–induced collagen deposition. 
 
Next, we examined the effect of mTOR inhibition on TGF-β1––induced changes in glucose 
metabolism. ATP-competitive mTOR inhibition with AZD8055 significantly inhibited the TGF-
β1––induced increase in glycolytic flux, represented by the lactate to glucose ratio measured in 
cell-conditioned media by 1H-NMR spectroscopy (Fig. 6F) and the TGF-β1––induced increase in 
ECAR (Fig. 6G). However, the TGF-β1––induced increase in gene expression of the key 
glycolytic genes LDHA and PFKFB3 (fig. S4, D and E) was insensitive to AZD8055 treatment 
(Fig. 6, H and I).  In contrast, and in agreement with our RNAseq dataset (Fig. 1C), AZD8055 
significantly inhibited the TGF-β1––induced increase in SLC2A1 mRNA abundance and GLUT1 
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protein abundance (Fig 6, J and K).  The increase in SLC2A1 mRNA abundance was Smad3- 
dependent but rapamycin-insensitive (fig. S4, G and H), Finally, silencing ATF4 using siRNA 
inhibited the TGF-β1––induced increase in SLC2A1 mRNA abundance and GLUT1 protein 
abundance (Fig. 6, L and M).  
 
The observation that AZD8055 attenuates TGF-β1––induced collagen deposition, de novo serine-
glycine pathway gene expression and glucose metabolism led us to speculate that mTOR 
signaling augments TGF-β1––induced collagen deposition by providing the glycolytic 
intermediates required for enhanced glycine and collagen synthesis.  Phosphoglycerate 
dehydrogenase (PHGDH) is the first rate-limiting enzyme that catalyzes 3-phospho-glycerate (3-
PG) from glycolysis into 3-phosphohydroxypyruvate (3-PHP).  Disrupting PHGDH using 
siRNA or inhibition of PHGDH with a selective pharmacological inhibitor (NCT-503)(33) 
blocked TGF-β1––induced collagen deposition (Fig. 6, N and O and fig. S4I). Moreover, glycine 
supplementation rescued the inhibitory effect of glucose deprivation on TGF- β1–induced 
collagen deposition by 70 +/- 12 % (Fig. 7A). Furthermore, glycine supplementation rescued the 
inhibitory effect of AZD8055 on the TGF-β1–induced collagen response by 58 ± 5% (Fig. 7B). 
In contrast, supplementation with the glycine precursor, serine, did not rescue this inhibitory 
effect (fig. S5A).   
 
We also performed experiments with exogenous radiolabeled glucose and glycine to determine 
whether they are incorporated into collagen α1(I) in response to TGF-β1 stimulation following 
isolation by immunoprecipitation (fig. S5B). Incorporation of either U-14C-glucose or U-14C-
glycine was assessed by scintillation counting. The expected pattern of collagen α1(I) production 
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in fibroblasts exposed to TGF-β1 and the impact of AZD8055 was observed following  
immunoprecipitation and visualization by western blot (Fig. 7C).  Analysis of U-14C-glucose 
incorporation into collagen α1(I) mirrored this pattern, with a 5-fold increase in U-14C-glucose 
incorporation into isolated collagen α1(I) in TGF-β1–stimulated fibroblasts compared with media 
alone-treated fibroblasts (Fig. 7D).  U-14C-glucose incorporation into collagen α1(I) was reduced 
to baseline values in TGF-β1–stimulated fibroblasts treated with AZD8055 (Fig. 7D).  We also 
examined whether exogenous U-14C-glycine was incorporated into collagen α1(I) in conditions 
where the TGF-β1–induced serine-glycine biosynthesis pathway was inhibited by AZD8055.  
Exogenous U-14C-glycine incorporation into collagen α1(I) was low in TGF-β1–stimulated cells 
in the absence of AZD8055 but increased 6-fold in the presence of AZD8055, indicating that 
exogenous glycine is utilized by TGF-β1–stimulated fibroblasts to mount a collagen response 
when the de novo serine-glycine pathway was inhibited by AZD8055 (Fig. 7E).  
 
Taken together, our data support the conclusion that the Smad3 signaling pathway and the 
mTORC1-4E-BP1 axis cooperate to enhance the production of ATF4 which in turn influences 
key ATF4 target genes in order to promote the biosynthesis of glycolysis-derived glycine to meet 
the collagen biosynthetic requirements of TGF-β1–activated myofibroblasts.  
 
 
Discussion  
 
Excessive extracellular matrix deposition by myofibroblasts is a key pathogenic pathway leading 
to fibrosis and has also been implicated in promoting cancer progression.  Previous data from our 
laboratory demonstrated a critical role for the mTORC1-4E-BP1 axis during TGF-β1–induced 
collagen deposition(27). In the present study, we now report a critical role for this axis, acting in 
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cooperation with Smad3 to promote the production of ATF4 which in turn orchestrates the 
subsequent transcriptional amplification of the glucose-derived serine-glycine biosynthetic 
pathway (Fig. 8). As well as furthering our understanding of the signaling and transcriptional 
events by which TGF-β1 reprograms fibroblast metabolism to promote collagen biosynthesis, 
these observations have important implications for the development of future therapeutic 
strategies.  
 
WGCNA analysis of our existing RNAseq dataset comparing the effect of ATP-competitive 
mTOR inhibition versus rapamycin on TGF-β1–induced human lung fibroblasts provided key 
insights into the potential mechanism by which mTOR influences collagen deposition. The initial 
motivation to exploit these pharmacological differences was predicated on previous studies that 
demonstrated that collagen deposition in activated fibroblasts and mesenchymal cells is sensitive 
to ATP-competitive mTOR inhibition but not to rapamycin treatment (27, 34, 35). These 
differences in pharmacological effect reflect the differential modes of mTOR inhibition by 
rapamycin and ATP-competitive mTOR inhibitors. Whereas the latter will block the 
phosphorylation sites on all downstream mTORC1 and mTORC2 substrates, rapamycin is a 
partial mTORC1 inhibitor which preferentially inhibits mTORC1 sites that are weakly 
phosphorylated by mTORC1 (p70S6K (Thr389) and 4E-BP1 (Ser65)).  In contrast, mTORC1 
substrates sites which are avidly phosphorylated by mTORC1 (4E-BP1 (Thr37/46) and 4E-BP1 
(Thr70)) are largely insensitive to rapamycin treatment (27, 36).   
The WGCNA module representing the profile of genes modulated by TGF-β1 treatment, 
sensitive to AZD8055 treatment but insensitive to rapamycin, comprised all four genes encoding 
the enzymes of the serine-glycine synthetic pathway (PHGDH, PSAT, PSPH and SHMT2) which 
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were present in the top 20 most correlated genes overall.  This finding merited further 
investigation given that glycine is present in every third amino acid position of the collagen 
molecule and is integral to the composition and stability of its triple helical structure (37). The 
observation that TGF-β1 stimulates the serine-glycine biosynthetic pathway to provide additional 
glycine needed for increased collagen synthesis is further in agreement with a recent report (38) 
and with the observation that pharmacologic inhibition of PHGDH attenuates fibrogenesis in 
vivo and also in the context of  TGF-β1–induced collagen deposition reported herein (39).  
 
In cancer cells, it is well-established that mTORC1 and its downstream substrate 4E-BP1, play 
critical roles in regulating metabolic pathways through the eIF4F complex-dependent translation 
of key transcription factors, including HIF1α and c-MYC (40). In our study, OCN identified 
several potential transcriptional regulators of interest, including notably ATF4. ATF4, a basic 
leucine zipper transcription factor, is a transcriptional master regulator of amino acid metabolism 
and stress responses and is classically enhanced as part of the integrated stress response (ISR) as 
a result of the activation of kinases, such as PERK and GCN2, which phosphorylate the 
translation factor eIF2α, leading to global reduction in mRNA translation except for select 
mRNAs, including ATF4 (41, 42). ATF4 in turn increases gene transcription by binding to the 
C/EBP–ATF response element (CARE) in the promoter of specific target genes (43–45). 
However, to the best of our knowledge, ATF4 had not previously been linked to TGF-β1-induced 
collagen deposition.   
 
In our fibroblast studies, we now provide evidence that TGF-β1 increases ATF4 production 
through the cooperation of both canonical Smad3 and mTOR signaling pathways.  Combining 
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data obtained from kinetic studies of the signaling response with our data obtained in function 
blocking studies based on pharmacological inhibition (AZD8055), siRNA for Smad3 and ATF4, 
CRISPR-Cas9 gene editing of RICTOR and RPTOR and 4E-BP1 phospho-mutants, we propose a 
model in which the Smad3 pathway plays a critical role in regulating ATF4 mRNA abundance in 
an mTOR-independent manner; whereas the mTORC1-4E-BP1 axis is critical for ATF4 
translation.  Moreover, the early increase in ATF4 protein abundance is likely explained by the 
Smad3-dependent mTOR mediated translation of existing ATF4 mRNA and is consistent with 
our previous report that Smad3 is critical for TGF-β1-mediated mTORC1 activation (27). This 
model is further consistent with our subsequent in silico analysis of the ATF4 gene promoter for 
Smad binding sequences.  Three different web-based platforms identified putative Smad2/3/4 
binding elements in the ATF4 promoter with a predicted Smad3 binding site located at base pairs 
-283 to -275 from the transcription start site. Furthermore, the activation of ATF4 in the absence 
of the eIF2α kinase-mediated integrated stress response (ISR) has also been reported in mouse 
embryonic fibroblasts (46).  
 
To the best of our knowledge, a key role for the mTORC1-4E-BP1 axis in mediating the 
stimulatory effects of TGF-β1 on ATF4 translation has not been previously reported but is in 
agreement with recent reports demonstrating a role for either mTORC1 (46) , or both mTORC1 
and 4E-BP1 in regulating the translation of ATF4 in other cell contexts (47). ATF4 gene 
disruption further demonstrated that ATF4 was necessary for TGF-β1–induced collagen 
deposition. Taken together with our recent report showing a role for mTORC1 and 4E-BP1 
during TGF-β1–induced collagen deposition(27), the data herein now provides strong evidence 
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for a key role for ATF4 downstream of the mTORC1-4E-BP1 axis in mediating the potent 
fibrogenic effects of TGF- β1. 
 
In terms of potential relevance of our findings to the human disease setting, we further provide 
evidence that ATF4 is expressed by α-SMA positive myofibroblasts within IPF fibrotic foci, as 
well as by the epithelium. This latter observation is broadly in agreement with a previous report 
focusing on the role of ATF4 in the context of epithelial endoplasmic reticulum stress and 
apoptosis in IPF using a polyclonal antibody against ATF4 (48). The ATF4 staining pattern in 
control lung is predominantly epithelial and is in agreement with the pattern reported by Human 
Protein Atlas (https://www.proteinatlas.org/ENSG00000128272-ATF4/tissue/lung). Our data 
therefore now extends our current understanding of the role of ATF4 in the transcriptional 
regulation of the serine-glycine pathway beyond the cancer setting, where this pathway has been 
strongly implicated in supporting cell growth and proliferation, as well as clinical aggressiveness 
in non-small cell lung cancer (NSCLC) (31, 49).  
 
We also herein provide evidence for the importance of both mTOR and ATF4 in regulating 
TGF-β1-induced increases in glycolysis. The first enzyme of the serine-glycine biosynthetic 
pathway (PHGDH) converts the glycolytic intermediate 3-phosphoglycerate (3PG) to 3-
phosphohydroxypyruvate (3PHP). Previous studies have shown that glycolysis is elevated in 
myofibroblasts (16, 38) but whether mTOR signaling in response to TGF-β1 stimulation 
contributes to this glycolytic response in fibroblasts was not known. We confirmed that TGF-β1–
stimulated myofibroblasts adopt a glycolytic phenotype and now provide further evidence that 
mTOR signaling plays a critical role in mediating these metabolic changes. However, although 
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the mTOR-ATF4 axis was found to regulate the expression of SLC2A1 and GLUT1, we found no 
role for mTOR in regulating the expression of the TGF-β1–induced glycolytic genes, PFKFB3 
and LDHA.  In terms of linking enhanced glycolysis to TGF-β1–induced collagen deposition, 
extracellular glycine supplementation partially rescued the inhibitory effect of glucose 
deprivation, as well as mTOR inhibition, on TGF-β1-induced collagen deposition. An enhanced 
demand for glucose to meet the biosynthetic demands of collagen production following TGF-β1 
stimulation is further supported by our observation that U-14C-glucose incorporation into 
collagen I is increased in TGF-β1-stimulated fibroblasts.  U-14C-glycine tracing experiments 
further demonstrated that exogenous glycine enables fibroblasts to generate a TGF-β1–induced 
collagen response when the de novo serine-glycine pathway is inhibited by mTOR inhibition 
with AZD8055. Taken together, these data support the notion that mTOR promotes glycolysis to 
generate the necessary glycine to support enhanced collagen production. The observation that 
ATF4 mediates the stimulatory effects of TGF-β1 on SLC2A1 expression is further potentially in 
agreement with a previous study which identified two enhancer binding elements in the 
regulatory elements of the SLC2A1 gene which contains the same CRE consensus binding site 
shared by ATF4 (50). 
 
It is also worth pointing out that the mechanism by which mTOR influences glycolysis in 
myofibroblasts contrasts with its role in cancer cells, where mTOR has been reported to promote 
the expression of multiple glycolytic genes by enhancing the translation of HIF1α and c-MYC 
(51–53). Although there is a degree of mechanistic overlap between cancer and fibrosis, the 
mutational landscapes are very different. mTOR is one of the most frequently mutated signaling 
hubs in cancer as a consequence of PI3K amplification/mutation, PTEN los
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overexpression, and S6K1, 4E-BP1 and eIF4E overexpression(54).  In contrast, mTOR pathway 
activation is likely to be a consequence of the altered tissue microenvironment in pathological 
fibrosis and in the stromal response in cancer, in that in both settings fibrogenesis is generally 
considered a reactive rather than a malignant process (55, 56). Of interest, although the 
mechanism is not known, IPF myofibroblasts have been reported to display evidence of PTEN 
deficiency (57). 
It is also worth commenting that in contrast to an absolute requirement for extracellular glucose, 
mitochondrial respiration was found to be dispensable for TGF-β1-induced collagen deposition, 
suggesting that glycolytic flux in response to TGF-β1 stimulation is sufficient to meet both the 
biosynthetic and energetic requirements of the complex multistage process of collagen 
biosynthesis in primary adult lung fibroblasts over the course of our experiments (48 hours). 
Additionally, increased mitochondrial biogenesis has been reported to be important for the 
maintenance of the differentiated and contractile myofibroblast state in a fetal lung fibroblast line 
(IMR-90) (15). These studies report that the expression of the TGF-β1-induced matrix 
glycoprotein, fibronectin, was also not dependent on mitochondrial biogenesis. We further 
provide herein evidence that mTOR inhibition does not interfere with TGF-β1-induced 
myofibroblast differentiation which is also in agreement with a previous report(58). Taken 
together, a picture now seems to be emerging that TGF-β1–induced fibroblast differentiation and 
matrix synthesis, the two cardinal features that define the myofibroblast phenotype, may have 
distinct metabolic requirements that could be targeted separately or in combination to slowdown 
both the restrictive physiologic impairment and the gas exchange impairment that characterize 
the fibrotic lung in IPF.  
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In conclusion, we present a novel mechanistic model in which ATF4 reconfigures the fibroblast 
biosynthetic and metabolic network to meet the collagen synthetic demands of highly activated 
myofibroblasts following TGF-β1 stimulation. As well as providing novel insight into the 
signaling and transcriptional pathways by which the major pro-fibrotic mediator TGF-β1 exerts it 
pro-fibrotic effects, our findings suggest that targeting the mTORC1-ATF4 axis might represent 
a novel approach for the future development of anti-fibrotic strategies. 
 
 
Materials and Methods 
 
Primary human fibroblast culture  
Primary human lung fibroblasts (pHLFs) were grown from explant cultures of healthy control 
lung tissue, as previously described (59). Human tissues were sourced ethically, and their 
research use was in accord with the terms of informed consents. Institutional research ethics 
committee approval for this work was obtained from the UCL Research Ethics Committee 
(12/EM/0058).  To avoid exposing cells to supra-physiological glucose and glutamine 
concentrations in standard DMEM, pHLFs (passage 4-8) were cultured in glucose and 
glutamine-free DMEM (Thermo-Fisher) that was supplemented with 10% fetal calf serum 
(Simga-Aldrich), 5mM glucose, 0.7mM glutamine (Thermo-Fisher) and 1% Penicillin 
(100U/ml)/ Streptomycin (100 μg/ml)(Thermo-Fisher) (referred throughout the manuscript as 
“growth media”). All fibroblast cultures tested negative for mycoplasma. 
 
A pHLF cell line expressing a dominant-negative mutant of 4E-BP1 was generated as described 
previously (27). Cells were selected with 2μg/ml puromycin (Sigma-Aldrich) for 4 days. 
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Expression of the 4E-BP1 mutant was induced with 1 μg/ml doxycycline (Sigma-Aldrich) for 24 
hour before treatment with or without TGF-β1.  After 24 hours pHLF lysates were analyzed for 
ATF4 abundance by immunoblotting. 
 
Real-time quantitative PCR (qPCR) analysis of gene expression 
Total RNA was extracted from adherent cells using RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions.  Real-time PCR was performed using a Mastercycler Realplex ep 
gradient S (Eppendorf). Specific primers were designed to detect the expression of genes (Table 
S2). PCR amplification was carried out for 40 cycles at a melting temperature of 95°C for 15 
seconds and an annealing temperature of 60°C for 60 sec. A dissociation curve was analyzed for 
each PCR experiment to assess primer-dimer formation or contamination. Relative expression 
was calculated using 2-ΔCt and ΔCt was calculated from the mean of two reference genes, ATP5B 
and β2 microglobulin (β2M) (PrimerDesign Ltd). 
 
Immunoblotting 
Adherent fibroblasts were washed with ice-cold PBS then lysed using Phosphosafe extraction 
reagent (Merck Millipore) supplemented with protease inhibitor (Merck Millipore). Equal 
protein quantities of lysate were separated by SDS-PAGE, transferred to nitrocellulose, and 
protein levels assessed by Western blotting with the following antibodies: P70S6K (CST #9202), 
Phospho-p70S6KThr389 (CST #9234), 4E-BP1 (CST #9644), Phospho-4E-BP1Ser65 (CST#9451), 
SMAD3 (CST #9523), Rictor (CST #2114), Raptor (CST#2280), GLUT1 (Abcam #EPR3915), 
PHGDH (CST #13428), PSAT (ThermoFisher #PA522124), PSPH (Insight Bio. #GTX109163-
S), SHMT2 (CST #12762), ATF4 (CST #11815), α-tubulin (CST #9099), Histone H4 (Abcam 
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#16483), Phospho-eIF2α(Ser51) (CST #3597) and eIF2α (#9722). The dilutions of primary and 
secondary antibodies were according to the manufacturer’s instructions. Tunicamycin (2µg/ml 
MP biomedicals) was used as a positive control for immunostaining of p-eIF2α. Protein band 
intensity was measured by densitometry in ImageQuant TL v8.1 (GE Healthcare) following 
electrochemiluminescence. All densitometries are presented relative to α-tubulin unless 
otherwise stated.  
 
Determination of collagen type I deposition by high-content imaging 
Extracellular collagen biosynthesis was measured in 96-well format by a high-content imaging 
based macro-molecular crowding assay as described previously (27). Briefly, confluent pHLFs 
were cultured in DMEM containing 0.4% FCS, 5 mM glucose, 0.7 mM L-glutamine and 
ascorbic acid (16.6µg/ml) in the presence of mixed Ficoll 70 and Ficoll 400 to facilitate 
molecular crowding. Following serum starvation for 24 hours, pHLFs were treated in the 
presence or absence of TGF-β1 (1 ng/ml) (R&D systems) with compounds AZD8055 (supplied 
by GSK, 1 µM used unless otherwise stated), Rapamycin (Millipore,100nm used unless 
otherwise stated), NCT-503 (20µM Sigma-Aldrich), GSK2656157(Cambridge Bioscience), 2-
deoxy glucose (Sigma-Aldrich, 3mM used) or vehicle (0.1% DMSO).  For rescue experiments, 
glycine (450 µM, Sigma Aldrich) and serine (Sigma-Aldrich) were used. After 48 hours, pHLFs 
were methanol-fixed and stained with antibodies to either human collagen I (C2456; Sigma) or 
α-smooth muscle actin (αSMA; (M085101-2, Thermo Fisher Scientific) followed by Alexa Fluor 
488 secondary antibody (A11001, Life Technologies) and nuclear DAPI counterstain.  
Fluorescent signal was captured and quantified using ImageXpress Micro XLS high-content 
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imaging system at 20x magnification (Molecular Devices), with 4 fields of view imaged per well 
and signal intensity normalized to cell count.  
 
Histology and immunohistochemistry 
All human samples were obtained with informed signed consent and with research ethics 
committee approval (10/H0504/9, 10/H0720/12 and 12/EM/0058). Patients with IPF were 
diagnosed in accordance with current international guidelines(60).  Immunostaining for ATF4 
and α-smooth-muscle actin was conducted on 10µm formalin-fixed paraffin-embedded serial 
sections of human lung biopsy material (N=3 patients with IPF and N=2 control subjects).  
Confocal dual-immunofluorescence for ATF4 (WH0000468M1, Sigma) was enhanced with 
streptavidin conjugated with Alexa Fluor® 488 (Thermo-Fisher) and co-localized with primary 
goat polyclonal α-smooth muscle actin (#PA5-18292, Thermo-Fisher) labeled with donkey anti-
goat Alexa fluor® 647 (Abcam), and counterstained with DAPI. Digitized images were captured 
on a Leica DM6000 CS microscope fitted with a Leica TCS SP8 confocal head and the Leica 
LAS-X software suite (Leica Microsystems GmbH). All images are representative and final 
images were prepared with Image J. 
 
NMR spectroscopy 
pHLFs were seeded in 6-well plates at 2x105 cells/ml and incubated in growth media for 3 days.  
Media were then replaced with serum-free media and cells were further cultured for 24 hours, at 
which point they were treated with or without TGF-β1 at 1ng/mL.  Cell supernatant was then 
collected and supplemented with 10% D2O for shift lock and 1mM TSP standard (Sigma). Using 
a 500MHz Bruker machine, 1H-spectra were obtained using a presaturation method after 128 
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scans. The resulting spectra were analyzed using ACD labs software (Advanced Chemistry 
Development UK Ltd) and integrals of the 5.2ppm peak and 1.3ppm peaks, corresponding to 
glucose and lactate respectively, were quantified relative to the internal TSP peak (0 ppm) 
standard.  
 
3H-2-DG uptake  
pHLFs were seeded in 6 well plates at 1 x105/ml and incubated in growth media for 3 days.  
Media were then replaced with serum free media for 24 hours. The next day, cells were treated 
with or without TGF-β1 at 1ng/mL. After 22 hours stimulation, media were changed to glucose-
free media for 2 hours. Cells were then washed with 0.5ml of Krebs-Ringer-HEPES (KRH) 
buffer. Cells were incubated in 2ml/well of KRH buffer that contained 5mM 2-deoxyglucose and 
0.625uCi/well 2-deoxy [3H] glucose (Perkin Elmer) for 5 mins.  The cells were washed 4 times 
with KRH buffer and lysed with 0.05mM NaOH for 2 hours at 370c.  Incorporated radioactivity 
in the cell lysate was determined by liquid scintillation counting. 
 
Assessment of extracellular acidification and oxygen consumption 
The Seahorse Bioscience XF96e extracellular flux analyzer was used to measure oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR). Briefly, pHLFs were 
seeded in XF96e microplates at 1x105 per well and incubated for 3 days in growth media. Media 
were then replaced with DMEM containing 0.4% FBS for 24 hours. The next day, cells were 
treated with or without TGF-β1 at 1ng/mL, in the presence (or absence) of AZD8055. The 
following day, media were replaced with assay media pre-warmed to 37°C supplemented with 
5mM glucose, 0.7 mM glutamine and 1mM pyruvate (Sigma S8636). Measurements of OCR and 
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ECAR were performed after equilibration in assay medium (lacking supplemental CO2) for about 
45 minutes. Oligomycin (Sigma O4876), FCCP (Sigma C2920), Antimycin A (Sigma A8674) 
and Rotenone (Sigma R8875) were added to perform a mitochondrial stress test as per the 
manufacturer’s instructions.  
 
Transcriptomic analysis by RNA sequencing 
Confluent fibroblast monolayers were untreated (“media alone”) or stimulated with TGF-β1 (and 
media) (1ng/ml, porcine origin, R&D Systems, USA) for 24 hours with and without AZD8055 
(1μM, synthesized and provided by GSK) or rapamycin (100nM, Merck Chemicals) in standard 
DMEM (N=4 biological replicates per condition). Total RNA was extracted with miRCURY 
RNA Isolation Kit (Exiqon). Poly(A)-tailed RNA enrichment and library preparation were 
performed using the KAPA Stranded mRNA-Seq Kit with KAPA mRNA Capture Beads 
(KAPABiosystems, Wilmington, MA, USA).  Paired-end RNA sequencing was performed with 
the NextSeq sequencing platform (Illumina, San Diego, CA, USA). Reads pre-processing and 
alignment to the genome (homo sapiens UCSC hg19) were performed using STAR aligner. 
Counts were normalised using the R package DeSeq2, then log2 transformed with an offset of 1 
and filtered to remove genes with an average count <1 across all samples. This left 15959 genes 
that were then interrogated using the weighted gene co-expression network analysis (WGCNA) 
package in R. Briefly, gene co-expression similarity was estimated by generating an absolute 
Pearson product moment correlation matrix. Using a soft threshold of 20, an adjacency matrix 
was calculated and used to estimate the topological overlap and assign genes to modules. Highly 
correlated modules were merged using a cut-height of 0.06 on the topological matrix 
dendrogram. Sixty-five modules were returned and assigned colours as names. MetaCore™ 
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(Thomson Reuter) was used to run pathway enrichment analyses and interaction network 
analyses on each of the 65 modules. Overconnected node analysis (OCN) was performed using 
the metabaseR R packages licensed from Clarivate Analytics and identifies one-step away direct 
regulators of the dataset that are statistically overconnected with the objects from the data set. 
The p-value of overconnectivity was calculated using hypergeometric distribution. 
 
In-silico prediction of SMAD2/3/4 binding sites in the ATF4 promoter 
The ATF4 promoter sequence was obtained from the eukaryotic promoter database (EPD) 
(Homo sapiens version 6, https://epd.vital-it.ch/human/human_database.php) (61). SMAD2/3/4 
binding site prediction was performed using web-based applications: EPD Search Motif Tool 
(using a cut-off p-value of 0.001), PROMO (http://alggen.lsi.upc.es/cgi-
bin/promo_v3/promo/promoinit.cgi?dirDB=TF_8.3) (62) (selecting eukaryote for factor’s and 
site’s species), and ConTra V3 (http://bioit2.irc.ugent.be/contra/v3/#/step/1) (63) (selecting 
visualization as type of analysis, human as reference organism and ATF4 sequence under 
identification number NM_182810). 
 
ATF4 protein stability 
Lysates were prepared from pHLFs stimulated with TGF-β1 (1 ng/ml) for 13 hours before pre-
treatment with DMSO or lactimidomycin (1 µM, Merck Millipore #506291) for 5 minutes, 
followed by exposure to DMSO or AZD8055 (1 µM) for 0/10/20/30/60 minutes before lysis. 
Immunoblotting was used to analyse the abundance of ATF4 normalised to α-tubulin.  
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Chromatin-bound protein fractionation  
Cell lysis and cytosolic extraction were performed following the manufacturer’ instructions (NE-
PER™, ThermoFisher). Nuclear extraction was performed by cell lysis in Buffer B (3mM 
EDTA, 0.2mM EGTA, 1mM DTT and protease inhibitor cocktail) for 30 minutes, followed by 
separation of soluble (nucleosoluble) and pellet (chromatin-bound) fractions by centrifugation at 
1700 x g 4°C for 5 minutes. Chromatin-bound protein pellet was washed in Buffer B before 
resuspension in laemmli buffer (4% SDS, 20% Glycerol, 10% 2-ME, 0.004% bromophenol blue, 
0.125M Tris HCl). 
 
siRNA-mediated protein expression knock-down 
For the determination of collagen deposition by molecular crowding assay, pHLFs were grown 
to confluence in our standard growth media in 96-well plates. During the serum-starvation period 
in growth media containing 0.4% FCS, cells were transfected with 10nM siRNAs  (Dharmacon, 
SMARTpool) targeting ATF4, PHGDH and SMAD3 using RNAiMax lipofectamine (Invitrogen) 
according to the manufacturer’s instructions. The following day, the media were replaced by 
Ficoll-containing media and the macro-molecular crowding assay was performed as described 
above. 
For western blotting and qPCR experiments, confluent pHLFs in 12-well plates were starved in 
serum-free media and transfected with 10nM siRNA (Dharmacon) using RNAiMax 
lipofectamine (Invitrogen) according to the manufacturer’s instructions. The following day, the 
media were replaced with fresh serum-free media with and without TGF-β1 (1 ng/ml) for the 
indicated time points.  
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CRISPR-Cas9 gene editing 
pHLFs were electroporated with a CRISPR ribonucleoprotein (RNP) complex using the Lonza 
4D Nucleofector™ system (Basel, Switzerland).  The guide RNA (gRNA) sequence targeting 
ATF4 (AGGTCTCTTAGATGATTACCTGG), RPTOR exon 26 
(CCGCGTCTACGACACAGAAGGATGG) or RICTOR exon 29 
(AATATCGGCTCATCAAATTGGGG were designed using a combination of previously 
published work (47), the Deskgen design platform 
(https://www.deskgen.com/guidebook/advanced.html) and the Integrated DNA technology 
online tool (https://eu.idtdna.com/site/order/designtool/index/CRISPR_CUSTOM).  A 
predesigned control gRNA sequence (Integrated DNA technology) was used to generate matched 
wildtype pHLFs. 
 
Incorporation of U-14C-glucose and U-14C-glycine into collagen I 
pHLFs were grown to confluence in 12-well plates and quiesced in serum-free media for 24 
hours.  Cells were then incubated in fresh serum-free media containing 5 mM 12C-glucose with 
or without 2 µCi U-14C-D-glucose (1 nM, Perkin Elmer). For glycine tracing studies, media 
containing 1 mM 12C-glycine, 1 mM 12C-glycine plus 2µCi U-14C-glycine (3.9 nM, Perkin 
Elmer) or media alone, was added to cells with either AZD8055 (1 µM) or vehicle (0.1% 
DMSO).  For TGF-β1–treated cells, TGF-β1 was added at (1 ng/ml).  After 48 hours cell layers 
were lysed (lysis buffer 300 mM NaCl, 10 mM Tris pH 7.4, 1% NP-40, protease-inhibitor) and 
pre-cleared with Protein G agarose beads (CST #37478) for 4 hours at 40C. Cleared lysates were 
immunoprecipitated with 1 µg anti-collagen α1(I) primary antibody (CST #84336) followed by 
Protein G agarose bead incubation overnight at 40C.  Immunoprecipitated material was then 
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eluted in LDS-containing sample buffer at 930C for 5 minutes, and incorporated radioactivity in 
the eluate determined by liquid scintillation counting (scintillated in Beckman Coulter LS6500 
using Ecoscint A (National diagnostics) scintillation fluid).  pHLF lysates incubated with 
corresponding treatments in the presence of 12C-glucose or 12C-glycine were also subjected to 
SDS-PAGE, transferred to PVDF and immunoblotted to determine collagen α1(I) abundance.  
To demonstrate immunoprecipitation efficiency, representative input (10%) and unbound (10%) 
portions were immunoblotted for collagen α1(I) alongside immunoprecipitated protein, antibody 
alone (0.4µg) and beads alone (10% slurry). 
 
Statistical analysis 
All data are expressed as means ± SEM and figures constructed using GraphPad Prism version 
7.00 and all experiments were repeated at least 3 times.  Statistical differences between two 
groups were analyzed using a standard two-tailed t-test (assuming unpaired data sets and unequal 
variances). When more than two groups were compared, either one-way or 2-way ANOVA was 
used with post-hoc application of the Tukey method.  Four-parameter non-linear regression 
analyses were used to generate IC50 values from concentration-response curves. The alpha level 
was set at 0.05 for all tests (GraphPad Prism). 
 
Supplementary Materials List 
fig. S1. TGF-β1 induced α-SMA expression is insensitive to AZD8055 treatment and the 
TGF-β1–induced serine-glycine biosynthetic pathway is insensitive to rapamycin treatment  
fig. S2. Demonstration of successful gene and protein manipulation and evidence that TGF-
β1 stimulation in fibroblasts is not associated with PERK activation 
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fig. S3 ATF4 knockdown abrogates the TGF-β1–induced increase in glycine biosynthesis 
enzyme protein production  
fig. S4. TGF-β1 increases glucose uptake, SLC2A1/GLUT1 and glycolytic enzyme 
expression 
fig. S5. Exogenous serine does not rescue the inhibitory effects of ATP-competitive mTOR 
inhibition on TGF-β1 induced collagen deposition 
Table S1. MetaCore pathways enriched in the rapamycin-insensitive mTOR module 
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Figures Legends  
Fig. 1.   Global transcriptomic analysis of TGF-β1––stimulated fibroblasts by RNAseq 
analysis reveals a rapamycin-insensitive mTOR-dependent serine-glycine biosynthetic 
signature during TGF-β1––induced collagen deposition  
 
(A) Plot showing scaled gene expression intensities from the rapamycin-insensitive mTOR 
module eigengene as calculated by WGCNA. The module eigengene is defined as the first 
principal component of the genes contained within the module and is representative of the gene 
expression profiles in the module. All expression values have been z transformed and signals that 
are negatively correlated to the module eigengene have been inverted for plotting (N=4 
biological replicates). (B) Bar plot showing the top 10 most significantly enriched pathways for 
the genes in the rapamycin-insensitive mTOR module. The serine-glycine biosynthesis pathway 
was most enriched (p-value = 5.45E-5).  (C) Heatmap representing the genes from the top 20 
most enriched pathways in the rapamycin-insensitive mTOR module, listed in order of the most 
to the least statistically significant. Genes that map to more than one pathway only appear for the 
pathway with the most significant p-value. Scaled counts were used to generate the heatmap, 
where darker red indicates higher number of counts. Black arrowheads indicate the genes 
belonging to the glycine metabolism pathway and the clear arrowhead indicates the SLC2A1 
gene (N=4 biological replicates). (D) Confluent primary human lung fibroblasts (pHLFs) were 
stimulated with media alone or media plus TGF-β1 and immunoblotting was performed for the 
indicated proteins (N=3 experiments, representative data shown). (E) Confluent pHLFs were 
pre-incubated with media plus vehicle (DMSO) or AZD8055 and stimulated for 48 h with or 
without TGF-β1. Collagen I deposition was assessed by high content imaging. IC50 value was 
calculated using four-parameter non-linear regression. Each data point shown is mean +/- SEM 
of the fold change to baseline of 3 biological replicates per condition and data are representative 
of 3 independent experiments. (F) Immunofluorescence staining showing collagen I deposition 
in pHLFs treated as in (E), scale bar =100 µm. (G) Confluent pHLFs were pre-incubated with 
media plus vehicle (DMSO) or rapamycin and stimulated for 48 hours with or without TGF-β1. 
Collagen I deposition was assessed by high content imaging. Each data point shown is mean +/- 
SEM of the fold change relative to baseline of 3 biological replicates per condition and the data 
are representative of 3 independent experiments. 
 
Fig. 2.  TGF-β1 amplifies the serine-glycine pathway in an mTOR-dependent manner 
 
Confluent pHLFs were incubated in media alone or media plus TGF-β1 with AZD8055 or 
vehicle control (DMSO) for 24 hours. (A-D) PHGDH, PSAT1, PSPH and SHMT2 relative 
mRNA abundance was quantified by RT-qPCR. Data are presented as means ± SEM from 3 
biological replicates.  (E, F) Immunoblots of protein lysates and densitometric quantification of 
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PHGDH (E) and PSPH (F) (N=3 biological replicates and data are representative of 3 
independent experiments).  Differences between groups were evaluated by two-way ANOVA 
test with Tukey post-hoc test. *p<0.05, **p<0.01, ***p< 0.001, ****p< 0.0001. 
 
 
Fig. 3.  Overconnected node analysis reveals a key role for mTOR in promoting ATF4 
protein production 
 
(A) Overconnected node analysis of the RNAseq data revealed a cluster of transcription factors 
associated with the serine-glycine module of enriched mRNAs. (B) Confluent pHLFs were 
incubated with or without TGF-β1 and ATF4 relative mRNA abundance was measured by RT-
qPCR over time (data are means ± SEM from 3 biological replicates). (C) Immunoblots and 
densitometric quantification of ATF4 protein abundance in pHLF lysates over time following 
TGF-β1 stimulation. Immunoblot shown represents ATF4 at 8 hours post TGF-β1 stimulation. 
Data are expressed as mean ± SEM from 3 biological replicates. (D) Relative ATF4 mRNA 
abundance measured at 24 hours post-TGF-β1 stimulation (N=3 biological replicates). (E) 
Immunoblot and densitometric quantification of ATF4 abundance at 24 hours post-TGF-β1 
stimulation (N=3 biological replicates). (F) Immunoblot and densitometric quantification of 
ATF4 abundance at indicated times post-TGF-β1 stimulation (N=3 biological replicates). (G) 
Confluent pHLFs were transfected with scrambled control siRNA (siCTRL) or  Smad3 siRNA 
(siSMAD3) and incubated with or without TGF-β1 and ATF4 relative mRNA abundance at 24 
hours was measured by RT-qPCR (N=3 biological replicates). (H, I)  ATF4 immunoblots and 
densitometric quantification represent samples analyzed at 8 hours (H) and 24 hours (I) (N=3 
biological replicates).  (J) pHLFs were pre-treated with TGF-β1 for 13 hours before treatment 
with lactimidomycin and vehicle (DMSO) or AZD8055.  Lysates were harvested at indicated 
times post-treatment and ATF4 abundance measured by immunoblotting and densitometric 
quantification (N=3 biological replicates). (K) pHLFs were modified by CRISPR-Cas9 gene 
editing of RPTOR or RICTOR  and stimulated with TGF-β1.  Immunoblot for ATF4 and 
densitometric quantification were performed at 24 hours (N=3 biological replicates). (L) pHLFs 
expressing a 4E-BP1-4A dominant-negative phospho-mutant were induced with doxycycline or 
media alone for 24 hours prior to TGF-β1 stimulation.  Immunoblot for ATF4 and densitometric 
quantification were performed at 18 hours post TGF-β1 stimulation (N=3 biological replicates). 
Differences between groups were evaluated by two-way ANOVA test with Tukey post-hoc test 
(B-I, L), repeated measures two-way ANOVA (J) or one-way ANOVA with Tukey post-hoc test 
(K). *p<0.05, **p<0.01, ***p< 0.001, ****p< 0.0001.   
 
 
Fig. 4. ATF4 co-localises with a-SMA-positive myofibroblasts within IPF fibrotic foci 
 
Immunofluoresence single staining for ATF4 (A, green), α-smooth muscle actin (B, α-SMA, red) 
and overlay of ATF4 and α-SMA (C, yellow) in a representative IPF fibrotic focus.  (A) Arrow 
indicates myofibroblasts within the fibrotic focus and arrowhead points to the hyperplastic 
epithelium.  Overlay of ATF4 and α-SMA in non-IPF lung tissue (D).  (E-G) Corresponding 
high magnification images of myofibroblasts within the fibrotic focus (indicated by arrow in A) 
for ATF4(E), α-SMA(F) and overlay of ATF4 and α-SMA(G).  (H) Mid-level non-composite 
confocal overlay image indicating nuclear localisation of ATF4 (green) in an α-SMA positive 
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myofibroblast cell (<0.5 µm).  All images counter-stained with DAPI (blue).  Scale A-D = 50 
µm, E-H = 25 µm, N=3 patients with IPF, N=2 control subjects and representative images 
shown. 
 
Fig. 5. ATF4-dependent modulation of the serine-glycine pathway is critical for TGF-β1––
induced collagen deposition 
 
(A) Confluent pHLFs were incubated with media plus TGF-β1 or media alone for 8 or 24 hours 
prior to cell lysis and separation into cytoplasmic (Cyto), nuclear (Nuc) and chromatin (Chrom) 
fractions. Immunoblots were then performed as indicated. (B-F) Confluent pHLFs were 
transfected with  scrambled control siRNA (siCTRL) or ATF4 siRNA (siATF4) before exposure 
to media plus TGF-β1 or media alone and the relative mRNA abundance of ATF4, PHGDH, 
PSAT1, PSPH and SHMT2 at 24 hours was measured by RT-qPCR (N=3 biological replicates). 
(G) Representative immunoblots for protein lysates treated as indicated in (B-F) are shown (N=3 
biological replicates and data are representative of 3 independent experiments). (H) Confluent 
pHLFs were transfected with scrambled control siRNA (siCTRL) or ATF4 siRNA (siATF4) 
before exposure to media plus TGF-β1 or media alone and collagen deposition assayed by high 
content imaging after 48 hours. (Each data point shown is mean +/- SEM of the fold change 
relative to baseline of 3-4 biological replicates per condition and data are representative of 3 
independent experiments). (I) Representative immunofluorescence images presented in (H) are 
shown, scale bar =100 µm. (J) Confluent wildtype and ATF4-/- crispred pHLFs were exposed to 
media plus TGF-β1 or media alone and collagen deposition assayed by high content imaging after 
48 hours (each data point shown is mean +/- SEM of the fold change relative to baseline of 3 
biological replicates per condition). Differences between groups were evaluated by two-way (B-
F, H, J) ANOVA test with Tukey post-hoc test. *p<0.05, **p<0.01,  
***p< 0.001, ****p< 0.0001. 
 
Fig. 6. mTOR amplifies glucose metabolism during TGF-β1––induced fibroblast collagen 
synthesis through an ATF4-dependent mechanism 
 
Confluent pHLFs were exposed to media plus TGF-β1 or media only for 24 hours. (A)The AUC 
of lactate  relative to AUC of glucose in cell supernatants was measured by NMR spectroscopy 
at the time points described (N=3 biological replicates and data are representative of 3 
independent experiments). (B, C) Confluent pHLFs were exposed to media plus TGF-β1 or 
media only for 24 hours. Extracellular acidification rate and oxygen consumption rate were 
measured using the SeaHorse XF96e assay (N=46 biological replicates and data are 
representative of 3 independent experiments). (D-E) Confluent pHLFs were incubated in media 
deplete of glucose (D) or pre-incubated with rotenone and antimycin A (E) and stimulated for 48 
hours with or without TGF-β1 and collagen deposition assessed by high content imaging. Each 
data point shown is mean +/- SEM of the fold change relative to baseline of 3 biological 
replicates and data are representative of 3 independent experiments. (F) Confluent pHLFs were 
pre-incubated with AZD8055 or vehicle control (DMSO) prior to exposure to media plus TGF-β1 
or media alone. The AUC of the lactate peak relative to AUC of the glucose peak in cell 
supernatant was measured by NMR spectroscopy after 24 hours (N= 3 biological replicates and 
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data are representative of 3 independent experiments). (G) The ECAR was assayed by SeaHorse 
XF96e after 24 hours with or without TGF-β1 stimulation (N=3 biological replicates and data are 
representative of 3 independent experiments). (H-K) Confluent pHLFs were pre-incubated with 
AZD8055 or vehicle control (DMSO) prior to TGF-β1 stimulation or media alone. Relative 
mRNA abundance of (H) PFKFB3, at 3 hours post TGF-β1 (I) LDHA and (J) SLC2A1, both at 
24 hours post TGF-β1 was measured by RT-qPCR (N=3 biological replicates) and (K) 
immunoblot for GLUT1 and densitometric quantification were performed (N=3 biological 
replicates). (L) Confluent pHLFs were transfected with scrambled control siRNA (siCTRL) or 
ATF4 siRNA (siATF4) exposed to media plus TGF-β1 or media only and relative mRNA 
abundance of SLC2A1 at 24 hours was measured by RT-qPCR (N=3 biological replicates, data 
representative of 3 independent experiments). (M) Representative immunoblots of protein 
lysates derived from pHLFs treated in same conditions as (L) are shown (N=3 biological 
replicates). (N) Confluent pHLFs were transfected with scrambled control siRNA(siCTRL) or 
PHGDH siRNA (siPHGDH) and exposed to media plus TGF-β1 or media only for 48 hours and 
collagen deposition assessed by high content imaging (each data point shown is mean +/- SEM 
of the fold change relative to baseline of 3 biological replicates). (O) pHLFs were treated with 
PHGDH inhibitor, NCT-503 (or DMSO control) and stimulated with or without TGF-β1 for 48 
hours. Collagen deposition was assessed by high content imaging, each data point represents 
mean +/- SEM of the fold change relative to baseline of 5 biological replicates per condition. 
Differences between groups were evaluated by unpaired t-test (B) or two-way ANOVA test with 
Tukey post-hoc test (A,C-O). *p<0.05, **p<0.01, ***p<0.001, ****p< 0.0001. 
 
Fig. 7. mTOR promotes glucose derived glycine biosynthesis to supply glycine during TGF-
β1––induced collagen synthesis 
 
(A) Confluent pHLFs were deprived of glucose for 24 hours and incubated with or without 
glycine, followed by incubation with or without TGF-β1 for 48 hours before assessment of 
collagen deposition by high content imaging (each data point shown is mean +/- SEM of the fold 
change relative to baseline of N=3 biological replicates per condition and data are representative 
of 3 independent experiments). (B) Confluent pHLFs were incubated with AZD8055 and 
supplemented 30 minutes later with or without glycine, then incubated with or without TGF-β1 
for 48 hours before assessment of collagen deposition by high content imaging. Each data point 
shown is mean +/- SEM of the fold change relative to baseline of 3 biological replicates and data 
are representative of 3 independent experiments. (C) Confluent pHLFs were incubated with 
AZD8055 or DMSO and exposed to media plus TGF-β1 or media alone in the presence of 12C-
glucose for 48 hours.  Collagen α1(I) was isolated by immunoprecipitation and immunoblotted. 
(D) Confluent pHLFs were incubated with AZD8055 or DMSO and exposed to media plus TGF-
β1 or media alone in the presence of U-14C-glucose for 48 hours. U-14C-glucose incorporation 
into immunoprecipitated collagen α1(I) was assessed by scintillation counting (N=3 biological 
replicates). (E) Confluent pHLFs were incubated with AZD8055 or DMSO and stimulated with 
TGF-β1 in the presence of U-14C-glycine for 48 hours. U-14C-glycine incorporation into 
immunoprecipitated collagen α1(I) was assessed by scintillation counting (N=3 biological 
replicates) and expressed relative to immunoprecipitated collagen α1(I) protein abundance 
determined in a parallel immunoblot. Differences between groups were evaluated by unpaired t-
test (E) or one way (A,B,D) ANOVA test with Tukey post-hoc test. *p<0.05, **p<0.01,  
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***p< 0.001, ****p< 0.0001. 
 
Fig. 8. Proposed mechanism by which ATF4 promotes the reconfiguration of myofibroblast 
metabolic and biosynthetic networks to support enhanced collagen biosynthesis in response 
to TGF-β1 stimulation.   
 
TGF-β1 ligation of the TGF-β receptor complex leads to a Smad3 dependent increase in ATF4 
mRNA abundance as well as mTOR activation.  Activated mTORC1/4E-BP1 signaling in turn 
promotes ATF4 protein production through a translational mechanism.  ATF4 subsequently 
promotes the transcriptional increase of SLC2A1/GLUT1 and key serine-glycine pathway genes.  
These then act together to promote glucose-derived glycine biosynthesis in order to support 
enhanced collagen synthesis rates in activated myofibroblasts.  (TGF-β1: Transforming growth 
factor β1; mTORC1: mechanistic target of rapamycin complex 1; GLUT1: glucose transporter 1; 
G6P: glucose 6-phosphate; 3-PG: 3-Phosphoglycerate; PHGDH: phosphoglycerate 
dehydrogenase; 3-PHP: 3-phosphohydroxypyruvate; PSAT1: phosphoserine aminotransferase 1; 
3PS: 3-phosphoserine; PSPH: phosphoserine phosphatase; SHMT2: serine 
hydroxymethyltransferase 2; OXPHOS: oxidative phosphorylation). 
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fig. S1. TGF-β1 induced α-SMA expression is insensitive to AZD8055 treatment and the 
TGF-β1 induced serine-glycine biosynthetic pathway is insensitive to rapamycin 
treatment 
 
(A-B) Confluent pHLFs were incubated with or without TGF-β1 for 1 hour followed by 
immunoblotting and densitometric quantification of p-p70S6K relative to p70S6k (Thr389)(A) 
and p-4E-BP1 relative to 4E-BP1(Ser65)(B), N=3 biological replicates and data are 
representative of 3 independent experiments. (C-D) Confluent pHLFs were pre-incubated 
with vehicle (DMSO) or increasing concentrations of AZD8055 and stimulated for 48 hours 
with TGF-β1. α-SMA stress fiber formation was assessed by high content imaging. 
Immunofluorescence images are shown as indicated (Scale bar=100µm) (C) and (D) N=3 
biological replicates and data are representative of 3 independent experiments. (E) SHMT1 
relative mRNA abundance was measured by RT-qPCR at 24 hours following incubation with 
media plus TGF-β1 or media alone (N=3 biological replicates). (F–I) Confluent pHLFs were 
pre-incubated with rapamycin or vehicle (DMSO) prior to TGF-β1 incubation or media alone. 
After 24 hours, the relative mRNA abundance of PHGDH, PSAT1, PSPH and SHMT2 were 
measured by RT-qPCR (N=3 biological replicates and data are representative of 3 
independent experiments).  Differences between groups were evaluated by unpaired t-test 
(A,B,E) or two-way ANOVA (F-I) with Tukey post-hoc testing. *p<0.05, **p<0.01, 
***p<0.001, ****p< 0.0001. 
 
  
 
 
 
fig. S2. Demonstration of successful gene and protein manipulation and evidence that 
TGF-β1 stimulation in fibroblasts is not associated with PERK activation  
 
(A) Confluent pHLFs were transfected with scrambled control siRNA (siCTRL) or Smad3 
siRNA (siSMAD3) before incubation with or without TGF-β1 for 24 hours. Representative 
immunoblot and densitometric quantification for Smad3 are shown (N=3 biological 
replicates). (B) Confluent pHLFs were treated with TGF-β1 for 13 hours and lactimidomycin 
was added followed by vehicle (DMSO) or AZD8055.   Immunoblotting for ATF4 and α-
tubulin was performed at indicated time points over the subsequent hour.  (C) pHLFs were 
modified by CRISPR-Cas9 gene editing of RPTOR or RICTOR before being incubated in 
media alone for 24 hours.  Immunoblot and densitometric quantification of Raptor and Rictor 
are shown (N=3 biological replicates). (D) Confluent pHLFs were treated with doxycycline 
or media alone for 24 hours prior to TGF-β1 stimulation.  Immunoblot for ATF4 and 
densitometric quantification were performed at 24 hours (N=3 biological replicates).  (E) 
Confluent pHLFs were incubated with or without TGF-β1 and immunoblotting and 
densitometric quantification for phosphorylated p-eIF2α and total-eIF2α were performed at 
indicated time points. Tunicamycin was added as a positive control and lysates collected at 
12 hours post TGF-β1 stimulation (N=3 biological replicates). (F) Confluent pHLFs were pre-
incubated with vehicle (DMSO) or the PERK inhibitor GSK2656157 and stimulated for 48 
hours with or without TGF-β1 and collagen deposition assessed by high content imaging. 
N=3 biological replicates per condition and data are representative of 3 independent 
experiments. Difference between groups were assessed by two-way ANOVA (A,E) with 
Tukey post-hoc test or unpaired T-test (C,D). *p<0.05, **p<0.01, ***p< 0.001, ****p< 
0.0001. 
 
  
 
 
fig. S3 ATF4 knockdown abrogates the TGF-β1–induced increase in glycine biosynthesis 
enzyme protein production.  
 
Confluent pHLFs were transfected with scrambled control siRNA (siCTRL) or ATF4 siRNA 
(siATF4) were incubated with or without TGF-β1 for 24 hours. Immunoblotting performed 
and densitometric quantification for ATF4(A), PHGDH(B), PSAT1(C), PSPH(D) and 
SHMT2(E) are presented (N=3 biological replicates). (F) Confluent wildtype and ATF4-/- 
crispred pHLFs were incubated with or without TGF-β1.  Representative immunoblotting and 
densitometric quantification for ATF4 are shown at 24 hours (N=3 biological replicates). 
Difference between groups were assessed by two-way ANOVA (A-E) with Tukey post-hoc 
test or unpaired T-test (F). *p<0.05, **p<0.01, ***p< 0.001, ****p< 0.0001. 
  
 
 
fig. S4. TGF-β1 increases glucose uptake, SLC2A1/GLUT1 and glycolytic enzyme 
expression 
 
(A) Confluent pHLFs were incubated with or without TGF-β1 for 24 hours and 3H-2DG 
uptake was measured (N=3 biological replicates and data are representative of 3 independent 
experiments). (B-E) Confluent pHLFs were incubated with or without TGF-β1 and (B) 
SLC2A1 relative mRNA abundance(24 hours), (C) GLUT1 protein abundance (24 hours),  
(D) PFKFB3 (3 hours) and (E) LDHA (24 hours) relative mRNA abundance were measured 
(N=3 biological replicates). (F) Confluent pHLFs were incubated in the presence of 2-
deoxyglucose and incubated for 48 hours with or without TGF-β1.  Collagen deposition at 48 
hours was assessed by high content imaging. N=3 biological replicates per condition and data 
are representative of 3 independent experiments. (G) Confluent pHLFs were transfected with 
scrambled control siRNA (siCTRL) or Smad3 siRNA (siSMAD3), before incubation with or 
without TGF-β1; SLC2A1 relative mRNA abundance was measured at 24 hours (N=3 
biological replicates). (H) Confluent pHLFs were pre-incubated with rapamycin (or DMSO 
control) and exposed to media plus TGF-β1 or media alone; SLC2A1 relative mRNA 
abundance was measured at 24 hours. (I) Confluent pHLFs were transfected with  scrambled 
control siRNA (siCTRL) or PHGDH siRNA (siPHGDH) before incubation with or without 
TGF-β1; immunoblotting and densitometric quantification of PHGDH were performed at 24 
hours (N=3 biological replicates).  Differences between groups were evaluated by unpaired t-
test (A-E) or two-way (F-I) ANOVA test with Tukey post-hoc test. *p<0.05, **p<0.01, 
***p< 0.001, ****p< 0.0001. 
 
  
 
fig. S5. Exogenous serine does not rescue the inhibitory effects of ATP-competitive 
mTOR inhibition of TGF-β1 induced collagen deposition 
 
(A) Confluent pHLFs were incubated with AZD8055 and supplemented with or without 
increasing concentration of serine as described, then incubated with or without TGF-β1; 
collagen deposition was assessed by high content imaging at 48 hours. N=3 biological 
replicates per condition and data are representative of 3 independent experiments. (B) 
Confluent pHLFs were stimulated with TGF-β1 prior to cell lysis and immunoprecipitated 
with antibodies targeting IgG or collagen α1(I), followed by immunoblotting for collagen 
α1(I) abundance in whole lysate (input), antibody-bound fraction (collagen α1(I) IP) and 
unbound fraction. Protein G agarose beads and collagen type α1(I) antibody alone were 
immunoblotted as controls.  Differences between groups were evaluated by one-way 
ANOVA test with Tukey post-hoc test (A). *=p<0.05, **=p<0.01, ***p< 0.001, ****p< 
0.0001.  
 
 
 
Table S1. MetaCore pathways enriched in the rapamycin-insensitive, mTOR module 
 
Pathway P value Genes 
Glycine, serine, cysteine and threonine metabolism 5.45E-05 CBS,GARS,PHGDH,PISD,PSAT1,PSPH,SHMT2 
Signal transduction_mTORC1 downstream signaling 0.000743439 CCND2,EIF4A2,EIF4EBP1,GRB10,MTHFD2,POLR3K, 
SLC2A1,SREBF2 
L-Alanine and L-cysteine metabolism 0.000942113 CBS,GOT1,GPT2,PC 
Translation_Insulin regulation of translation 0.002325036 EIF2B3,EIF2S2,EIF2S3,EIF4A2,EIF4EBP1,TSC1 
Translation_Translation regulation by Alpha-1  
adrenergic receptors 
0.004874917 ADRA1B,EIF4A2,EIF4EBP1,GNB1,GNG11,RHOA 
Tau pathology in Alzheimer disease 0.007691877 GPC1,GRIN2A,MARK1,SDC1,SDC2,TUBA1B,TUBB4B 
Hypertrophy of  asthmatic airway smooth muscle cells  0.009638728 EIF2B3,EIF2S2,EIF2S3,EIF4EBP1,IFNAR2,MAX 
Immune response_Distinct metabolic pathways in naive  
and effector CD8+ T cells 
0.011569384 EIF4EBP1,SLC1A5,SLC2A1,SLC7A5,TSC1 
Translation_Opioid receptors in regulation of translation  0.013771852 EIF4EBP1,GNB1,GNG11,PENK 
Apoptosis and survival_Endoplasmic reticulum stress 
response pathway 
0.014249639 BAK1,BCL2L11,EIF2S2,EIF2S3,HERPUD1 
Folic acid metabolism 0.016973265 ALDH1L2,MTHFD2,SHMT2 
Stem cells_Excitotoxicity of Glutamate in glioblastoma 0.017731496 GNB1,GNG11,GOT1,GRIN2A 
Regulation of lipid metabolism_Alpha-1 adrenergic 
receptors signaling via arachidonic acid 
0.018431849 ADRA1B,GNB1,GNG11,PTGS1,RHOA 
Fenofibrate in treatment of type 2 diabetes and  
metabolic syndrome X 
0.01906206 ABCA1,ACSL4,RBP4 
DeltaF508-CFTR traffic / Sorting endosome formation in CF 0.021286737 NSF,RAB7A,VPS25 
Apoptosis and survival_Role of nuclear PI3K in  
NGF/ TrkA signaling 
0.023647542 ACIN1,BCL2L11,NPM1 
Role of ER stress in obesity and type 2 diabetes 0.024016297 ATF3,PCK2,SREBF2,TRIB3 
Transcription_HIF-1 targets 0.025269769 ADRA1B,CCNG2,LOXL2,LOXL4,NPM1,SLC2A1 
Cysteine-glutamate metabolism 0.027393787 CBS,GOT1 
Muscle contraction_S1P2 receptor-mediated  
smooth muscle contraction 
0.031496271 GNB1,GNG11,MYL7,RHOA 
Proteolysis_Role of Parkin in the 
Ubiquitin-Proteasomal Pathway 
0.032207644 PSMD11,SIAH2,TUBA1B,TUBB4B,UBE2G2 
Sulfur metabolism 0.032360777 CBS,GOT1 
Apoptosis and survival_Granzyme A signaling 0.033557078 ANP32A,APEX1,HIST1H2BD,HIST2H2BE 
Neurophysiological process_Dynein-dynactin motor complex 
in axonal transport in neurons 0.037276388 DYNLRB2,IPO5,MAPRE3,RAB7A,TUBA1B,TUBB4B 
Development_PIP3 signaling in cardiac myocytes 0.042916214 CCND2,EIF4EBP1,GNB1,GNG11,TSC1 
Stem cells_Role of GSK3 beta in cardioprotection against 
myocardial infarction 0.043951681 ADM2,BDKRB2,PENK 
Transcription_CoREST complex-mediated epigenetic gene 
silencing 0.045019326 ELAC2,GRIN2A,SIN3A,SMARCC1 
Signal transduction_AKT signaling 0.04754385 BCL2L11,CCND2,EIF4EBP1,TSC1 
 
 
Table S2. Primer sequence 
 
 
 
  
 
 
ATF4 (F) 5'-GCTAAGGCGGGCTCCTCCGA-3' 
ATF4 (R) 5'-ACCCAACAGGGCATCCAAGTCG-3' 
LDHA (F) 5’-GGAGATTCCAGTGTGCCTGT-3’ 
LDHA (R) 5’-GTCCAATAGCCCAGGATGTG-3’ 
PFKFB3 (F) 5’-AAAAGTGTTCAACGTCGGGG-3’ 
PFKFB3 (R) 5’-CATGGCTTCCTCATTGTCGG-3’ 
PHGDH (F) 5’-GGAGGAGATCTGGCCTCTCT-3’ 
PHGDH (R) 5’-GTCATTCAGCAAGCCTGTCG-3’ 
PSAT1 (F) 5’-GCGGCCATGGAGAAGCTTAG-3’ 
PSAT1 (R) 5’-ATGCCTCCCACAGACACGTA-3’ 
PSPH (F) 5’-GAGGACGCGGTGTCAGAAAT-3’ 
PSPH (R) 5’-GGTTGCTCTGCTATGAGTCTCT-3’ 
SHMT1 (F) 5’-GTGACCACCACCACTCACAA-3’ 
SHMT1 (R) 5’-ACAGCAACCCCTTTCCTGTAG-3’ 
SHMT2 (F) 5’-GCTGCCCTAGACCAGAGTTG-3’ 
SHMT2 (R) 5’-GCAGAGGCCGAGCCG-3’ 
SLC2A1 (F) 5’-ACTGTCGTGTCGCTGTTTGT-3’ 
SLC2A1 (R) 5’-GATGGCCACGATGCTCAGAT-3’ 
